DESTINY-Breast11 - Business-News-Today.com

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

Representative image of an oncology consultation for HER2-positive early breast cancer, as AstraZeneca and Daiichi Sankyo’s Enhertu FDA approval expands treatment options before and after surgery in the United States.

Read More

Pharma Industry News

AstraZeneca, Daiichi Sankyo secure FDA approval for Enhertu in two early breast cancer indications

Enhertu is moving from late-stage control to early-stage cure. AstraZeneca and Daiichi Sankyo now face the bigger test: adoption.

May 16, 2026

web analytics